Document Detail

Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase.
MedLine Citation:
PMID:  23324897     Owner:  NLM     Status:  Publisher    
This study aimed at comparing the effects of atorvastatin and vitamin E on erectile dysfunction in patients initially irresponsive to sildenafil, with investigation into the underlying possible mechanisms. Sixty patients were randomly divided into three groups: the atorvastatin group received 80 mg daily, the vitamin E group received 400 IU daily and the control group received placebo capsules. Patients were examined both before and after 6 weeks of treatment for biochemical tests; Superoxide dismutase (SOD), glutathione peroxidase (GPO), C-reactive protein (CRP), interleukin-6 (IL-6), nitric oxide (NO) and endothelial nitric oxide synthase (eNOS) and for erectile function tests; International index of erectile function (IIEF-5) scores and Rigiscan. Both atorvastatin and vitamin E showed a statistically significant GPO increase (P<0.05) and a statistically significant IL-6 decrease (P<0.05). Only atorvastatin showed a statistically significant increase in NO (15.19%, P<0.05), eNOS (20.58%, P<0.01), IIEF-5 score (53.1%, P<0.001) and Rigiscan rigidity parameters (P<0.01), in addition to a statistically significant decrease in CRP (57.9%, P<0.01). However, SOD showed a statistically significant increase only after vitamin E intake (23.1%, P<0.05). Both atorvatstain and vitamin E had antioxidant and anti-inflammatory activities. Although activating eNOS by atorvastatin was the real difference, and expected to be the main mechanism for NO increase and for improving erectile dysfunction. Atorvastatin, but not vitamin E, is a promising drug for sildenafil nonresponders.International Journal of Impotence Research advance online publication, 17 January 2013; doi:10.1038/ijir.2012.46.
A A El-Sisi; S K Hegazy; K A Salem; K S Abdelkawy
Related Documents :
10567867 - Visual outcome after treatment with low-dose recombinant tissue plasminogen activator o...
21776097 - Physical illnesses among elderly psychiatric out-patients with depression.
21701627 - Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerab...
22052407 - Optimal sample sizes for phase ii clinical trials and pilot studies.
1396427 - Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of int...
21678347 - Topical anaesthetics for repair of dermal laceration.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-17
Journal Detail:
Title:  International journal of impotence research     Volume:  -     ISSN:  1476-5489     ISO Abbreviation:  Int. J. Impot. Res.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007383     Medline TA:  Int J Impot Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Professor of Pharmacology and Toxicology, Pharmacology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of charge state on gas-phase behaviors of noncovalent protein complexes in collision induced ...
Next Document:  Using a cervical spine cage to reconstruct malunited fibular fractures.